How does Riomet work?

This unique liquid formulation of metformin, Riomet®, works by the same mechanism as the tablet form to improve glucose tolerance in patients with Type 2 diabetes.

Riomet (Metformin) is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Riomet (Metformin) decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Unlike sulfonylureas,Riomet (metformin) does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects (except in special circumstances, see PRECAUTIONS in Prescribing Information) and does not cause hyperinsulinemia.

With Riomet (metformin) therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

Notes:

* Hypoglycemia, also called low blood sugar, occurs when your blood glucose (blood sugar) level drops too low to provide enough energy for your body's activities

** Hyperinsulinemia is an endocrine disorder characterized by a failure of the Blood Sugar Control System (BSCS) to work properly

	Important Safety Information about RIOMET® RIOMET as monotherapy, is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients 10 years of age and older with type 2 diabetes. RIOMET may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults (17 years of age and older). RIOMET is contraindicated in patients with renal disease or dysfunction, acute or chronic metabolic acidosis, including diabetic ketoacidosis or known hypersensitivity to Metformin hydrochloride. RIOMET treatment should not be initiated in patients >= 80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing lactic acidosis. In addition, RIOMET should be promptly withheld in the presence of any condition associated with hypoxemia, dehydration, or sepsis. Temporarily discontinue in patients receiving intravascular iodinated contrast materials for radiologic studies. Diarrhea, nausea, vomiting, abdominal bloating, anorexia, or flatulence may occur, especially during initiation of therapy. Not recommended for pediatric patients (under 10 years of age) or pregnant women. Hypoglycemia does not occur in patients receiving RIOMET alone under usual circumstances of use. Hypoglycemia could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Please see full Prescribing Information, including boxed WARNING regarding lactic acidosis Please consult with your healthcare professional to see if RIOMET is right for you. The content of this Web site is not a substitute for professional medical advice and should not be interpreted as treatment recommendations or relied on for medical diagnosis or treatment.

	Copyright 2004-2005 © - Ranbaxy Laboratories, Inc. \| Privacy Policy \| Sitemap \| This site is intended for use by U.S. residents only